441
Views
70
CrossRef citations to date
0
Altmetric
Drug Profile

Droxidopa in neurogenic orthostatic hypotension

, &

References

  • FDA. Definition of orphan disease and orphan products. (editors) 2012
  • Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 2011;21(2):69-72
  • Goldstein DS, Holmes CS, Dendi R, et al. Orthostatic hypotension from sympathetic denervation in Parkinson’s disease. Neurology 2002;58(8):1247-55
  • Kaufmann H, Biaggioni I. Autonomic failure in neurodegenerative disorders. Semin Neurol 2003;23(4):351-63
  • Freeman R. Clinical practice Neurogenic orthostatic hypotension. N Engl J Med 2008;358(6):615-24
  • Masaki KH, Schatz IJ, Burchfiel CM, et al. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. Circulation 1998;98(21):2290-5
  • Berganzo K, Diez-Arrola B, Tijero B, et al. Nocturnal hypertension and dysautonomia in patients with Parkinson’s disease: are they related? J Neurol 2013;260(7):1752-6
  • Palma JA, Gomez-Esteban JC, Norcliffe-Kaufmann L, et al. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go? Mov Disord 2015
  • Kaufmann H. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin Auton Res 1996;6(2):125-6
  • Horowitz DR, Kaufmann H. Autoregulatory cerebral vasodilation occurs during orthostatic hypotension in patients with primary autonomic failure. Clin Auton Res 2001;11(6):363-7
  • Arnold AC, Biaggioni I. Management approaches to hypertension in autonomic failure. Curr Opin Nephrol Hypertens 2012;21(5):481-5
  • . Dopamine Beta-Hydroxylase Deficiency. In: GeneReviews(R). Robertson D, Garland EMPagon RA, et al. Eds. (Seattle (WA) 1993
  • Norcliffe-Kaufmann L, Axelrod F, Kaufmann H. Afferent baroreflex failure in familial dysautonomia. Neurology 2010;75(21):1904-11
  • Palma JA, Carmona-Abellan MM, Barriobero N, et al. Is cardiac function impaired in premotor Parkinson’s disease? A retrospective cohort study. Mov Disord 2013;28(5):591-6
  • Norcliffe-Kaufmann L, Kaufmann H. Is ambulatory blood pressure monitoring useful in patients with chronic autonomic failure? Clin Auton Res 2014;24(4):189-92
  • Ejaz AA, Kazory A, Heinig ME. 24-hour blood pressure monitoring in the evaluation of supine hypertension and orthostatic hypotension. J Clin Hypertens (Greenwich) 2007;9(12):952-5
  • Shibao C, Lipsitz LA, Biaggioni I. ASH position paper: evaluation and treatment of orthostatic hypotension. J Clin Hypertens (Greenwich) 2013;15(3):147-53
  • Schroeder C, Jordan J, Kaufmann H. Management of neurogenic orthostatic hypotension in patients with autonomic failure. Drugs 2013;73(12):1267-79
  • Perera R, Isola L, Kaufmann H. Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure. Clin Auton Res 1995;5(4):211-13
  • Weinberg AD, Minaker KL. Dehydration. Evaluation and management in older adults. council on scientific affairs, American Medical Association. JAMA 1995;274(19):1552-6
  • Krediet CT, van Lieshout JJ, Bogert LW, et al. Leg crossing improves orthostatic tolerance in healthy subjects: a placebo-controlled crossover study. Am J Physiol Heart Circ Physiol 2006;291(4):H1768-72
  • Wieling W, van Lieshout JJ, van Leeuwen AM. Physical manoeuvres that reduce postural hypotension in autonomic failure. Clin Auton Res 1993;3(1):57-65
  • May M, Jordan J. The osmopressor response to water drinking. Am J Physiol Regul Integr Comp Physiol 2011;300(1):R40-6
  • McHugh J, Keller NR, Appalsamy M, et al. Portal osmopressor mechanism linked to transient receptor potential vanilloid 4 and blood pressure control. Hypertension 2010;55(6):1438-43
  • MacLean AR, Allen EV. Orthostatic hypotension and orthostatic tachycardia - Treatment with the “head-up” bed. J Am Med Assoc 1940;115:2162-7
  • Diedrich A, Biaggioni I. Segmental orthostatic fluid shifts. Clin Auton Res 2004;14(3):146-7
  • Smit AA, Wieling W, Fujimura J, et al. Use of lower abdominal compression to combat orthostatic hypotension in patients with autonomic dysfunction. Clin Auton Res 2004;14(3):167-75
  • Kooner JS, Raimbach S, Watson L, et al. Relationship between splanchnic vasodilation and postprandial hypotension in patients with primary autonomic failure. J Hypertens Suppl 1989;7(6):S40-1
  • Berne C, Fagius J, Niklasson F. Sympathetic response to oral carbohydrate administration. Evidence from microelectrode nerve recordings. J Clin Invest 1989;84(5):1403-9
  • Jansen RW, Lipsitz LA. Postprandial hypotension: epidemiology, pathophysiology, and clinical management. Ann Intern Med 1995;122(4):286-95
  • Chobanian AV, Volicer L, Tifft CP, et al. Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med 1979;301(2):68-73
  • Norcliffe-Kaufmann L, Axelrod FB, Kaufmann H. Developmental abnormalities, blood pressure variability and renal disease in Riley Day syndrome. J Hum Hypertens 2013;27(1):51-5
  • Kaufmann H, Brannan T, Krakoff L, et al. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology 1988;38(6):951-6
  • Wright RA, Kaufmann HC, Perera R, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology 1998;51(1):120-4
  • Ramirez CE, Okamoto LE, Arnold AC, et al. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension 2014;64(6):1235-40
  • Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006;63(4):513-18
  • Jordan J, Shannon JR, Biaggioni I, et al. Contrasting actions of pressor agents in severe autonomic failure. Am J Med 1998;105(2):116-24
  • Hoeldtke RD, Israel BC. Treatment of orthostatic hypotension with octreotide. J Clin Endocrinol Metab 1989;68(6):1051-9
  • Ooi WL, Hossain M, Lipsitz LA. The association between orthostatic hypotension and recurrent falls in nursing home residents. Am J Med 2000;108(2):106-11
  • Rosenmund KW, Dornsaft H. Über Oxy- und Hioxyphenylserin und die Muttersubstanz des Adrenalins. Ber Dtsch Chem Ges 1919;52:1734-49
  • Blaschko H, Holton P, Stanley GH. The decarboxylation of -3: 4-dihydroxyphenylserine (noradrenaline carboxylic acid). Br J Pharmacol Chemother 1948;3(4):315-19
  • Beyer KH, Blaschko H, Burn JH, Langemann H. Enzymic formation of noradrenaline in mammalian tissue extracts. Nature 1950;165(4206):926
  • Blaschko H, Burn JH, Langemann H. The formation of noradrenaline from dihydroxyphenylserine. Br J Pharmacol Chemother 1950;5(3):431-7
  • Schmiterlow CG. The formation in vivo of noradrenaline from 3:4-dihydroxyphenylserine (noradrenaline carboxylic acid). Br J Pharmacol Chemother 1951;6(1):127-34
  • Araki H, Tanaka C, Fujiwara H, et al. Pressor effect of L-threo-3,4-dihydroxyphenylserine in rats. J Pharm Pharmacol 1981;33(12):772-7
  • Suzuki T, Higa S, Sakoda S, et al. Orthostatic hypotension in familial amyloid polyneuropathy: treatment with DL-threo-3,4-dihydroxyphenylserine. Neurology 1981;31(10):1323-6
  • Biaggioni I, Robertson D. Endogenous restoration of noradrenaline by precursor therapy in dopamine-beta-hydroxylase deficiency. Lancet 1987;2(8569):1170-2
  • Man in ’t Veld AJ, Boomsma F, van den Meiracker AH, Schalekamp MA. Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in dopamine-beta-hydroxylase deficiency. Lancet 1987;2(8569):1172-5
  • Birkmayer W, Birkmayer G, Lechner H, Riederer P. DL-3,4-threo-DOPS in Parkinson’s disease: effects on orthostatic hypotension and dizziness. J Neural Transm 1983;58(3-4):305-13
  • Sakoda S, Suzuki T, Higa S, et al. Treatment of orthostatic hypotension in Shy-Drager syndrome with DL-threo-3,4-dihydroxyphenylserine: a case report. Eur Neurol 1985;24(5):330-4
  • Senda Y, Muto T, Matsuoka Y, et al. [Clinical effects of oral L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in patients with Shy-Drager syndrome]. Rinsho Shinkeigaku 1987;27(3):300-4
  • Kachi T, Iwase S, Mano T, et al. Effect of L-threo-3,4-dihydroxyphenylserine on muscle sympathetic nerve activities in Shy-Drager syndrome. Neurology 1988;38(7):1091-4
  • Iida N, Tsubakihara Y, Shirai D, et al. Treatment of dialysis-induced hypotension with L-threo-3,4-dihydroxyphenylserine. Nephrol Dial Transplant 1994;9(8):1130-5
  • Bartholini J, Constantinidis J, Puig M, et al. The stereoisomers of 3,4-dihydroxyphenylserine as precursors of norepinephrine. J Pharmacol Exp Ther 1975;193(2):523-32
  • Inagaki C, Fujiwara H, Tanaka C. Inhibitory effect of (+)threo-3,4-dihydroxy-phenylserine (DOPS) on decarboxylation of (-)threo-dops. Jpn J Pharmacol 1976;26(3):380-2
  • Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology 2014;83(4):328-35
  • Kaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation 2003;108(6):724-8
  • Goldstein DS, Holmes C, Kaufmann H, Freeman R. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res 2004;14(6):363-8
  • Goldstein DS. L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc Drug Rev 2006;24(3-4):189-203
  • Ishikawa Y, Kato Y, Murakami Y, et al. Effect of L-threo-3,4-dihydroxyphenylserine (L-DOPS) on catecholamine levels in plasma and cerebrospinal fluid (CSF) in anesthetized rats. Proc Soc Exp Biol Med 1987;184(2):197-200
  • Tohgi H, Abe T, Takahashi S. The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients. J Neural Transm Park Dis Dement Sect 1993;5(1):27-34
  • Tohgi H, Abe T, Takahashi S, et al. Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients. Neurosci Lett 1990;116(1-2):194-7
  • Hoeldtke RD, Cilmi KM, Mattis-Graves K. DL-Threo-3,4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension. Clin Pharmacol Ther 1984;36(3):302-6
  • Freeman R, Landsberg L, Young J. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology 1999;53(9):2151-7
  • Kaufmann H, Oribe E, Yahr MD. Differential effect of L-threo-3,4-dihydroxyphenylserine in pure autonomic failure and multiple system atrophy with autonomic failure. J Neural Transm Park Dis Dement Sect 1991;3(2):143-8
  • Mathias CJ, Senard JM, Braune S, et al. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res 2001;11(4):235-42
  • Kaufmann H, Malamut R, Norcliffe-Kaufmann L, et al. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res 2012;22(2):79-90
  • Biaggioni I, Freeman R, Mathias CJ, et al. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension 2015;65(1):101-7
  • Hauser RA, Isaacson S, Lisk JP, et al. Droxidopa for the Short-Term Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Parkinson’s Disease (nOH306B). Mov Disord 2014
  • Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson’s disease (NOH306A). J Parkinsons Dis 2014;4(1):57-65
  • Yamamoto K, Morita S, Ikeda S, Yanagisawa N. [Hyperthermia in a Shy-Drager syndrome patient–pathophysiological effects of body temperature and L-DOPS on orthostatic hypotension]. Rinsho Shinkeigaku 1993;33(1):68-73
  • Ueda M, Hamamoto M, Otsubo K, et al. [Monoamine imbalance of the central nervous system in a case of Shy-Drager syndrome with recurrent attacks of a neuroleptic malignant syndrome]. Rinsho Shinkeigaku 1996;36(5):696-8
  • Yoshikawa H, Oda Y, Sakajiri K, et al. Pure akinesia manifested neuroleptic malignant syndrome: a clinical variant of progressive supranuclear palsy. Acta Neuropathol 1997;93(3):306-9
  • Tanaka H, Yamaguchi H, Mino M. The effects of the noradrenaline precursor, L-threo-3,4-dihydroxyphenylserine, in children with orthostatic intolerance. Clin Auton Res 1996;6(4):189-93
  • Kaufmann H. Could treatment with DOPS do for autonomic failure what DOPA did for Parkinson’s disease? Neurology 1996;47(6):1370-1
  • Yoshikawa H, Kawai K, Inoue S, et al. [A case of diabetic orthostatic hypotension effectively managed with L-dops (L-threo-3,4-dihydroxyphenylserine)]. Nihon Naika Gakkai Zasshi 1987;76(11):1695-700
  • Wecht JM, Rosado-Rivera D, Weir JP, et al. Hemodynamic effects of L-threo-3,4-dihydroxyphenylserine (Droxidopa) in hypotensive individuals with spinal cord injury. Arch Phys Med Rehabil 2013;94(10):2006-12
  • Muneta S, Iwata T, Hiwada K, et al. Effect of L-threo-3, 4-dihydroxyphenylserine on orthostatic hypotension in a patient with spinal cord injury. Jpn Circ J 1992;56(3):243-7
  • Akizawa T, Koshikawa S, Iida N, et al. Clinical effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients. Nephron 2002;90(4):384-90
  • Freeman R, Young J, Landsberg L, Lipsitz L. The treatment of postprandial hypotension in autonomic failure with 3,4-DL-threo-dihydroxyphenylserine. Neurology 1996;47(6):1414-20

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.